A new trading day began on Tuesday, with LENZ Therapeutics Inc (NASDAQ: LENZ) stock price up 5.95% from the previous day of trading, before settling in for the closing price of $25.7. LENZ’s price has ranged from $16.53 to $50.40 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -181.63% over the past five years. Meanwhile, its annual earnings per share averaged -10.77%. With a float of $27.68 million, this company’s outstanding shares have now reached $28.59 million.
LENZ Therapeutics Inc (LENZ) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of LENZ Therapeutics Inc is 11.54%, while institutional ownership is 90.62%. The most recent insider transaction that took place on Nov 17 ’25, was worth 1,024,000. Before that another transaction happened on Nov 07 ’25, when Company’s Director bought 10,500 for $22.79, making the entire transaction worth $239,278. This insider now owns 10,500 shares in total.
LENZ Therapeutics Inc (LENZ) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.46 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.76% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
Here are LENZ Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 48.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -2.76 in one year’s time.
Technical Analysis of LENZ Therapeutics Inc (LENZ)
LENZ Therapeutics Inc (NASDAQ: LENZ) saw its 5-day average volume 1.16 million, a positive change from its year-to-date volume of 0.47 million. As of the previous 9 days, the stock’s Stochastic %D was 79.21%.
During the past 100 days, LENZ Therapeutics Inc’s (LENZ) raw stochastic average was set at 20.62%, which indicates a significant decrease from 55.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.29 in the past 14 days, which was lower than the 2.38 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.42, while its 200-day Moving Average is $30.93. Nevertheless, the first resistance level for the watch stands at $28.04 in the near term. At $28.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $30.36. If the price goes on to break the first support level at $25.72, it is likely to go to the next support level at $24.21. Assuming the price breaks the second support level, the third support level stands at $23.40.
LENZ Therapeutics Inc (NASDAQ: LENZ) Key Stats
With a market capitalization of 852.02 million, the company has a total of 31,290K Shares Outstanding. Currently, annual sales are 0 K while annual income is -49,770 K. The company’s previous quarter sales were 12,500 K while its latest quarter income was -16,700 K.
